MHRA warns of pulmonary aspiration risk for GLP-1 receptor agonists during general anaesthesia or deep sedation

A review has found that all available data support a risk of pulmonary aspiration from glucagon-like peptide-1 or dual glucose-dependent insulinotropic polypeptide receptor agonists, owing to their association with delayed gastric emptying.
Healthcare professional putting her patient under anaesthesia
In response to the findings, the product information for glucagon-like peptide-1 or dual glucose-dependent insulinotropic polypeptide receptor agonists has been updated to include the risk of aspiration under general anaesthesia

Shutterstock.com

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned healthcare professionals to be aware of the potential risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1 RAs), who undergo surgery or procedures with general anaesthesia or deep sedation.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated